CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
OPERATING EXPENSES
General and administrative	$ 373	$ 245	$ 1,047	$ 956
Research and development	865	958	2,667	2,619
Total operating expenses	1,238	1,203	3,714	3,575
Interest and other income, net	(4)	(1)	(67)	(155)
Loss from continuing operations before taxes	1,234	1,202	3,647	3,420
Income tax benefit	0	0	0	(21)
NET LOSS	1,234	1,202	3,647	3,399
Less: Net Loss attributable to the noncontrolling interest	0	0	0	(193)
Net Loss attributable to Capstone Therapeutics Corp. stockholders	$ 1,234	$ 1,202	$ 3,647	$ 3,206
Per Share Information:
Net loss, basic and diluted, attributable to Capstone Therapeutic Corp. stockholders (in dollars per share)	$ 0.03	$ 0.03	$ 0.09	$ 0.08
Basic and diluted shares outstanding (in shares)	40,885	40,885	40,885	40,885